Effects of a New Combination of Nutraceuticals with Morus alba on Lipid Profile, Insulin Sensitivity and Endotelial Function in Dyslipidemic Subjects. A Cross-Over, Randomized, Double-Blind Trial

High Blood Pressure and Cardiovascular Prevention

Volumn 22, Issue 2, 2015, Pages 149-154

  Trimarco, Valentina ^a   Izzo, Raffaele ^a   Stabile, Eugenio ^a   Rozza, Francesco ^a   Santoro, Mario ^a   Manzi, Maria Virginia ^a   Serino, Federica ^a   Giacomo Schiattarella, Gabriele ^a   Esposito, Giovanni ^a   Trimarco, Bruno ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Hypercholesterolemia; Insulin sensitivity; Nutraceuticals

Indexed keywords

ASTAXANTINE PLUS BERBERINE PLUS COENZYME Q10 PLUS FOLIC ACID PLUS POLICOSANOL PLUS MONACOLIN K PLUS RED YEAST RICE; BERBERINE PLUS MONACOLIN K PLUS MORUS ALBA LEAF EXTRACT PLUS RED YEAST RICE POWDER; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MULBERRY EXTRACT; NUTRACEUTICAL; PLACEBO; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANTILIPEMIC AGENT; BERBERINE; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; HEMOGLOBIN A1C PROTEIN, HUMAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; MEVINOLIN; PLANT EXTRACT;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIPID METABOLISM; MALE; MORUS ALBA; PATIENT COUNSELING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; ADVERSE EFFECTS; AGED; BLOOD; DIETARY SUPPLEMENT; DRUG EFFECTS; DYSLIPIDEMIAS; INSULIN RESISTANCE; ITALY; METABOLISM; MIDDLE AGED; MORUS; PATHOPHYSIOLOGY; PLANT LEAF; TIME FACTOR; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM; VASODILATATION;

AGED; BERBERINE; BIOMARKERS; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; DYSLIPIDEMIAS; ENDOTHELIUM, VASCULAR; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; INSULIN; INSULIN RESISTANCE; ITALY; LIPIDS; LOVASTATIN; MALE; MIDDLE AGED; MORUS; PLANT EXTRACTS; PLANT LEAVES; TIME FACTORS; TREATMENT OUTCOME; VASODILATION;

EID: 84930938641     PISSN: 11209879     EISSN: 11791985     Source Type: Journal    
DOI: 10.1007/s40292-015-0087-2     Document Type: Article

References (17)

1. European Association for Cardiovascular P, Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, et al. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32(14):1769–818.
2. Izzo R, de Simone G, Giudice R, Chinali M, Trimarco V, De Luca N, et al. Effects of nutraceuticals on prevalence of metabolic syndrome and on calculated Framingham Risk Score in individuals with dyslipidemia. J Hypertens. 2010;28(7):1482–7.
3. Libby P. The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol. 2005;46(7):1225–8.
4. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med. 2004;141(6):413–20.
5. Gast KB, Tjeerdema N, Stijnen T, Smit JW, Dekkers OM. Insulin resistance and risk of incident cardiovascular events in adults without diabetes: meta-analysis. PLoS One. 2012;7(12):e52036.
6. Wang Y, Xiang L, Wang C, Tang C, He X. Antidiabetic and antioxidant effects and phytochemicals of mulberry fruit (Morus alba L.) polyphenol enhanced extract. PLoS One. 2013;8(7):e71144.
7. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159–219.
8. Gargiulo P, Marciano C, Savarese G, D’Amore C, Paolillo S, Esposito G, et al. Endothelial dysfunction in type 2 diabetic patients with normal coronary arteries: a digital reactive hyperemia study. Int J Cardiol. 2013;165(1):67–71.
9. Julious SA. Sample sizes for clinical trials with normal data. Stat Med. 2004;23(12):1921–86.
10. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–9.
11. Affuso F, Ruvolo A, Micillo F, Sacca L, Fazio S. Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study. Nutr Metab Cardiovasc Dis. 2010;20(9):656–61.
12. Yang X, Yang L, Zheng H. Hypolipidemic and antioxidant effects of mulberry (Morus alba L.) fruit in hyperlipidaemia rats. Food Chem Toxicol. 2010;48(8–9):2374–9.
13. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ, et al. Translating the A1C assay into estimated average glucose values. Diabetes care. 2008;31(8):1473–8.
14. Marciano C, Galderisi M, Gargiulo P, Acampa W, D’Amore C, Esposito R, et al. Effects of type 2 diabetes mellitus on coronary microvascular function and myocardial perfusion in patients without obstructive coronary artery disease. Eur J Nucl Med Mol Imaging. 2012;39(7):1199–206.
15. Van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, Rutten GE, Van Weel C. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2005(2):CD003639.
16. Derosa G, Romano D, D’Angelo A, Maffioli P. Berberis aristata combined with Silybum marianum on lipid profile in patients not tolerating statins at high doses. Atherosclerosis. 2015;239(1):87–92.
17. Di Pierro F, Putignano P, Villanova N, Montesi L, Moscatiello S, Marchesini G. Preliminary study about the possible glycemic clinical advantage in using a fixed combination of Berberis aristata and Silybum marianum standardized extracts versus only Berberis aristata in patients with type 2 diabetes. Clin Pharmacol. 2013;5:167–74.